CD33 and acute myeloid leukemia: In 2017, GO was approved by the US Food and Drug Administration (FDA) for the treatment of newly diagnosed CD33 + AML in adults in combination with chemotherapy, or as a single agent in relapsed or refractory (R/R) CD33 + AML in adults and pediatric patients ≥2 years old [35].